Cortexyme Inc.

35.68+3.80+11.92%Vol 268.81K1Y Perf -13.69%
Apr 13th, 2021 16:00 DELAYED
BID35.68 ASK35.78
Open31.88 Previous Close31.88
Pre-Market- After-Market-
 - -  - -%
Target Price
71.67 
Analyst Rating
Moderate Buy 1.67
Potential %
100.87 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-68/-74/2 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-31/-45/41 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-29/-44/29 
Income Ranking
 —    -
Market Cap1.05B 
Earnings Rating
Neutral
Price Range Ratio 52W %
27.90 
Earnings Date
11th May 2021

Today's Price Range

31.8835.82

52W Range

26.6658.99

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
8.32%
1 Month
-10.06%
3 Months
11.81%
6 Months
-27.05%
1 Year
-13.69%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CRTX35.683.800011.92
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.60-0.73-21.67
Q02 2020-0.63-0.604.76
Q01 2020-0.43-0.61-41.86
Q04 2019-0.39-0.46-17.95
Q03 2019--0.37-
----
----
----
Earnings Per EndEstimateRevision %Trend
12/2020 FY-2.59-1.97Negative
3/2021 QR-0.63-23.53Negative
6/2021 QR-0.65-14.04Negative
12/2021 FY-2.73-1.87Negative
Next Report Date11th May 2021
Estimated EPS Next Report-0.63
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume268.81K
Shares Outstanding29.55M
Trades Count3.40K
Dollar Volume11.98M
Avg. Volume304.72K
Avg. Weekly Volume262.55K
Avg. Monthly Volume301.51K
Avg. Quarterly Volume327.13K

Cortexyme Inc. (NASDAQ: CRTX) stock closed at 35.68 per share at the end of the most recent trading day (a 11.92% change compared to the prior day closing price) with a volume of 268.97K shares and market capitalization of 1.05B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. Cortexyme Inc. CEO is Casey C. Lynch.

The one-year performance of Cortexyme Inc. stock is -13.69%, while year-to-date (YTD) performance is 28.44%. CRTX stock has a five-year performance of %. Its 52-week range is between 26.66 and 58.99, which gives CRTX stock a 52-week price range ratio of 27.90%

Cortexyme Inc. currently has a PE ratio of -13.70, a price-to-book (PB) ratio of 6.16, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.97%, a ROC of -44.96% and a ROE of -53.42%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cortexyme Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.63 for the next earnings report. Cortexyme Inc.’s next earnings report date is 11th May 2021.

The consensus rating of Wall Street analysts for Cortexyme Inc. is Moderate Buy (1.67), with a target price of $71.67, which is +100.87% compared to the current price. The earnings rating for Cortexyme Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cortexyme Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cortexyme Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.22, ATR14 : 3.80, CCI20 : -32.80, Chaikin Money Flow : -0.20, MACD : -0.29, Money Flow Index : 40.02, ROC : 8.55, RSI : 60.09, STOCH (14,3) : 65.16, STOCH RSI : 1.00, UO : 41.68, Williams %R : -34.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cortexyme Inc. in the last 12-months were: Casey C. Lynch (Sold 90 000 shares of value $3 377 211 ), David A. Lamond (Buy at a value of $10 961 150), Leslie Holsinger (Option Excercise at a value of $11 745), Leslie Holsinger (Sold 40 000 shares of value $1 232 528 ), Michael Detke (Option Excercise at a value of $38 109)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Moderate Buy
1.67

Cortexyme Inc.

Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains. The company operates in only one reportable segment that is developing and commercializing therapeutics.

CEO: Casey C. Lynch

Telephone: +1 415 910-5717

Address: 269 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

News

Stocktwits